IMAGINE Asthma Study — Now Enrolling
Phase 3b Clinical Research Study for Severe Eosinophilic Asthma | Plantation, FL
About the IMAGINE Study
The IMAGINE Study is a Phase 3b clinical research program sponsored by GlaxoSmithKline (GSK). It is designed to evaluate how an investigational monoclonal antibody — depemokimab — affects the structure and function of the airways in people living with severe asthma driven by eosinophilic (Type 2) inflammation.
Depemokimab works by targeting interleukin-5 (IL-5), a key driver of eosinophilic airway inflammation. It is administered as an injection twice per year — a significantly less frequent dosing schedule than many current biologic therapies.
The study uses advanced imaging (high-resolution CT scanning) and bronchoscopic airway sampling to measure how the airways respond to treatment over time.
This is investigational research. Participation does not guarantee therapeutic benefit. Always consult your physician before making any medical decisions.
Study At a Glance
Study ID: NCT06979323
Phase: 3b
Sponsor: GlaxoSmithKline (GSK)
Drug: Depemokimab (anti-IL-5)
Condition: Severe eosinophilic asthma
Site: Advanced Asthma Clinic, Plantation FL
PI: Frank Hull, MD
FL Sites: One of two active Florida sites
Who May Qualify?
You may be eligible to participate in the IMAGINE Study if you meet all of the following criteria. These are general descriptions — only a clinician can determine your eligibility.
Possible Inclusion Criteria
- Asthma diagnosis for 2 or more years
- Blood eosinophil count of 300 cells/µL or higher at screening, or a documented history of that level within the prior 3 months
- Fractional exhaled nitric oxide (FeNO) of 25 ppb or higher at screening
- Two or more asthma exacerbations requiring oral or systemic corticosteroids in the past 12 months, despite medium- or high-dose inhaled corticosteroid (ICS) therapy
- Poorly controlled asthma (ACQ-5 score above 1.5)
- Pre-bronchodilator FEV1 below 80% of predicted value
- Currently on at least one additional controller medication besides ICS — such as a LABA, LAMA, or leukotriene receptor antagonist — for at least 3 months
Possible Exclusion Criteria
- Current smoker, or smoking history of 20 or more pack-years
- Asthma exacerbation within the past 4 weeks
- Diagnosis of hypereosinophilic syndrome or another significant lung condition besides asthma
- Prior anti-IL-5 or anti-IL-5 receptor therapy that did not provide meaningful benefit
- Metal implants or devices that could interfere with CT imaging
These are not the complete eligibility criteria. A study coordinator will review your full medical history during a no-cost screening visit to determine whether you are eligible to participate. Participation is voluntary.
What Does Participation Involve?
No-Cost Screening
A no-cost eligibility screening at our Plantation, FL clinic. No obligation to enroll.
Study Drug
Depemokimab administered by injection at the clinic every 6 months. All study-related medications provided at no cost.
Advanced Imaging
High-resolution CT scans and bronchoscopic airway sampling at specified timepoints — all study-related procedures at no cost.
Compensation
Compensation for time and travel is available for qualified participants who complete study visits.
About Depemokimab
Depemokimab is an investigational ultra-long-acting monoclonal antibody that targets IL-5, a cytokine central to eosinophilic inflammation in the airways. It is being evaluated across multiple Phase 3 programs for severe eosinophilic asthma. The IMAGINE study specifically focuses on understanding how this drug changes airway structure and cellular composition over time using high-resolution CT imaging and bronchoscopic sampling techniques.
Regulatory status: Depemokimab has not been approved by the FDA. As an investigational therapy, its full safety and efficacy profile continues to be evaluated in clinical trials conducted under FDA and IRB oversight.
About Our Research Site
Advanced Asthma Clinic and Lung Research Florida are clinical research facilities in Plantation, Florida led by Dr. Frank Hull, MD. Dr. Hull is a board-certified pulmonologist with over 20 years of experience in pulmonary medicine and clinical research, and has participated in numerous multi-center respiratory trials sponsored by major pharmaceutical and biopharmaceutical organizations.
Our Plantation site is one of two active Florida sites participating in the IMAGINE study. Our research team provides a transparent, participant-centered environment — you will understand every step of the study before committing.
For Referring Physicians
We are actively enrolling qualified patients in the IMAGINE Study (NCT06979323). If you have patients with severe eosinophilic asthma who remain poorly controlled on ICS-based therapy, they may be candidates for this study.
Broad eligibility summary:
- Severe eosinophilic asthma: blood eos ≥300 cells/mcL AND FeNO ≥25 ppb
- Two or more exacerbations in past 12 months on medium/high-dose ICS plus controller
- Uncontrolled symptoms (ACQ-5 > 1.5), pre-BD FEV1 < 80% predicted
- No prior anti-IL-5 or anti-IL-5R therapy failure
- Non-smoker or fewer than 20 pack-years
All referred patients receive a no-cost screening visit. We will keep you informed of your patient's study status.
Important Disclosures
This page is published by a clinical research site participating in the IMAGINE study — it does not constitute a physician consultation or medical advice. Clinical trials are investigational research studies; participation does not guarantee any therapeutic benefit. The IMAGINE study (NCT06979323) is conducted under IRB/ethics board approval and in full compliance with ICH-GCP guidelines and applicable FDA regulations. All participants provide written informed consent prior to any study procedures. Participation is completely voluntary. Always consult your physician before making any medical decisions. ClinicalTrials.gov registry: NCT06979323.
Interested in Participating?
Contact our Lung Research Florida team for a no-obligation eligibility discussion. The initial screening visit is at no cost to you.
GSK National Study Line: 877-379-3718 | ClinicalTrials.gov: NCT06979323